119 drugs added to China’s reimbursement list, which includes more domestic PD-1s

Negotiated additions to China’s National Reimbursement Drug List continue to drive down drug prices and expand access to checkpoint inhibitors, a category increasingly covered by domestic companies.

Of the 162 drugs that underwent price negotiations, 119 were added to the list with an average price reduction of nearly 51%. The additions are expected to reduce patient costs by about RMB28 billion ($4.3 billion) in 2021, according to the National Healthcare Security Administration (NHSA), which published the negotiation results on Monday. ...